A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
